ArticleProgress in neuro-psychopharmacology & biological psychiatry2026
Contributions of the interaction between mu-opioid receptors and dopamine receptors in the regulation of risky decision making.
Article in Progress in neuro-psychopharmacology & biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
During decision making, the ability to appropriately weigh potential risks against their associated rewards is necessary to navigate daily life. Prior work has established a critical role for dopamine (DA) D2 receptors (D2Rs) in this process, with activation of these receptors decreasing choice of risky options. Much less is known, however, about how other neuromodulatory systems, such as the endogenous opioid system, contribute to risk-based decision making and whether these systems interact with D2R regulation of risky choice. To begin to address this gap in knowledge, the goals of the current study were to identify the role of mu-opioid receptors (MORs) in decision making involving risk of punishment and to determine whether interactions between MORs and D2Rs are necessary to drive adaptive decision-making behavior. Drug-naïve male and female rats were trained on a punishment-based decision-making task in which rats chose between a small, safe food reward and a larger food reward accompanied by a variable risk of footshock punishment. Following training, effects of a MOR antagonist (Experiment 1), a D2R antagonist and MOR agonist (Experiment 2), a D2R agonist and MOR antagonist (Experiment 3), or an indirect catecholaminergic agonist and MOR antagonist (Experiment 4) on decision making were evaluated. The MOR antagonist naltrexone had no effect on lever presses for the large, risky reward (i.e., risk taking) or for the small, safe reward in either sex. The MOR agonist morphine, regardless of D2R inactivation, also did not affect risk taking, although it did decrease lever presses for the small, safe reward. When MORs were blocked with an antagonist, a selective D2R agonist caused a significant decrease in risk taking relative to vehicle conditions. The indirect catecholamine agonist amphetamine, however, decreased risk taking irrespective of whether MORs were blocked. Collectively, these findings suggest that although MOR activation alone is not necessary for decision making involving risk of punishment, the interaction between D2Rs and MORs may be an important mechanism underlying processes contributing to punishment-based decision making. Future studies will expand on this work by identifying where in the brain this interaction occurs to influence risk taking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.